$MRK Just Got a New Reason to Run
$Merck(MRK)$
$Merck & Co., Inc.(MRK) Rallies +1.42% to $149.86: Pharma Giant Nears 52-Week High with Bullish MACD Momentum, $156 Target in Focus 📈💊
Latest Close Data: MRK closed at $149.86 (+1.42%) on Sep 2, 2026, just 4.5% below its 52-week high of $156.92. Volume was 9.87M shares (Volume Ratio 0.98), turnover rate 0.40%.
Core Market Drivers: HSBC upgraded MRK from Hold to Buy on Sep 1, fueling the 2.6% pre-market pop. The mRNA cancer vaccine (intismeran autogene + Keytruda) Phase III success continues to attract analyst upgrades. Morgan Stanley lifted PT from $116 to $179 with Overweight rating.
Technical Analysis: MACD remains bullish with DIF 5.91 > DEA 5.71, histogram positive at 0.38. RSI(6) at 58.7 and RSI(24) at 63.7 — momentum recovering but not overbought. KDJ shows K=50.6, D=65.9, J=20.2, suggesting short-term consolidation after pullback.
Key Price Levels:
-
Primary Support: $116.72 (Sep 1 low)
-
Strong Resistance: $152.18 (recent pivot high) → then $156.92 (52-week high)
-
Immediate Pivot: $150.00 (round number + pre-market level)
Valuation Perspective: Forward P/E at 53.8x is far above the 24.8x historical average and +1 Std.Dev band of 45.9x. TTM P/E is 117.7x, P/S 5.55x — valuation remains stretched versus peer median.
Analyst Targets: 28 analysts with mean target of $145.77 (range $95–$186). Ratings: 7 Strong Buy, 16 Buy, 9 Hold. Morgan Stanley’s new $179 target implies +19% upside.
Weekly Outlook: Expect MRK to test $150 psychological level first. A breakout above $152.18 opens path to $156.92 (52-week high). Failure to hold $147.76 (yesterday close) could retest $140 support. Consolidation range: $144–$154.
⚠️ Risk Disclaimer: This technical analysis is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results. Trading involves substantial risk.
🎯$Merck & Co., Inc.(MRK) Options Strategy: Bull Call Spread (Debit Spread)
-
Underlying: MRK (Merck & Co., Inc.)
-
View: Moderately bullish; expecting a test of the $152.18 pivot high and a potential breakout toward the 52-week high of $156.92, supported by bullish MACD momentum and recent analyst upgrades (HSBC Buy, Morgan Stanley OW with $179 PT).
-
Strategy Type: Debit Spread / Defined Risk Bullish
-
Option Contract Portfolio:
-
Buy to Open: MRK 2026-09-18 145 Call @ $5.90 (mid)
-
Sell to Open: MRK 2026-09-18 155 Call @ $0.86 (mid)
-
Note: The 145 call has high open interest (779) and is one strike below current price ($149.86), offering a good balance of intrinsic + extrinsic value. The 155 call sits just above the recent pivot high ($152.18) and below the 52-week high ($156.92), acting as a realistic short-term cap.
-
-
Max Gain & Loss:
-
Max Gain: (Width of spread − Net Debit) = ($10.00 − $5.04) × 100 = $496 per spread
-
Max Loss: Net Debit paid = $504 per spread
-
-
Initial Cost/Credit: Net Debit of $5.04 (or $504 per contract)
Investing is a long journey. Knowing when to move matters — and so does knowing when to recharge.
Markets may not slow down, but you can. Whether it’s a quick break between trading sessions or a long journey, staying comfortable helps you reset for what comes next. The new Night Trading Memory Foam Pillow features 360° ergonomic support and slow-rebound memory foam that gently conforms to your neck, plus a roll-up design that makes it easy to bring wherever you go.
https://laohu8.com/J/redeemGift?goodID=100540&type=delivery
Redeem the new Night Trading Memory Foam Pillow in Tiger Coins Mall, and stay supported for the journey ahead.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

